Evidence map›Paper›PMID 30971317›Full record

ArticleActa veterinaria Scandinavica2019

Acute kidney injury management using intermittent low efficiency haemodiafiltration in a critical care unit: 39 dogs (2012-2015).

Maxime Cambournac, Isabelle Goy-Thollot, Julien Guillaumin, Jean-Yves Ayoub, Céline Pouzot-Nevoret, Anthony Barthélemy, Jeanne-Marie Bonnet-Garin

Open access · goldAbstract read
In one paragraph

Article in Acta veterinaria Scandinavica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Successful hemodialysis treatment of suspected acorn toxicosis in a Bedlington terrier.The Canadian veterinary journal = La revue veterinaire canadienne · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Maxime CambournacIntensive Care Unit (SIAMU), Université de Lyon, VetAgro Sup, APCSe, 69280, Marcy l'Etoile, France. maxime.cambournac@gmail.com.ORCID http://orcid.org/0000-0003-3522-2255
Isabelle Goy-ThollotIntensive Care Unit (SIAMU), Université de Lyon, VetAgro Sup, APCSe, 69280, Marcy l'Etoile, France.
Julien GuillauminEmergency and Critical Care Service, Department of Veterinary Clinical Sciences, The Ohio State University, Columbus, OH, 43210, USA.
Jean-Yves AyoubPhysiology Unit, Université de Lyon, VetAgro Sup, APCSe, 69280, Marcy l'Etoile, France.
Céline Pouzot-NevoretIntensive Care Unit (SIAMU), Université de Lyon, VetAgro Sup, APCSe, 69280, Marcy l'Etoile, France.
Anthony BarthélemyIntensive Care Unit (SIAMU), Université de Lyon, VetAgro Sup, APCSe, 69280, Marcy l'Etoile, France.
Jeanne-Marie Bonnet-GarinPhysiology Unit, Université de Lyon, VetAgro Sup, APCSe, 69280, Marcy l'Etoile, France.
Université Claude Bernard Lyon 1 · FRThe Ohio State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVeterinary studies describing acute kidney injury (AKI) management using renal replacement therapy (RRT) are limited and have primarily focused on intermittent haemodialysis in North American populations. European data are lacking, although differences in populations, pathogen and toxin exposure and RRT modalities may exist between Europe and North America. The present study reviewed RRT-managed cases from the intensive care unit (ICU) of VetAgro Sup, Lyon, France, for the period 2012-2015. The aims were to describe a 4-h RRT protocol of intermittent low efficiency haemodiafiltration, population characteristics and outcomes in canine AKI cases requiring RRT and to identify prognostic variables. We defined DeltaCreat/h as the difference between the serum creatinine level after RRT treatment N and that before treatment N + 1 divided by the time between treatments (in hours).

resultsThirty-nine dogs were included, and 67% were males. The median (range) age, weight, hospitalization length and number of RRT treatments were 4.4 (0.25-15) years, 26.6 (6.7-69) kg, 8 (1-23) days and 3 (1-8) treatments, respectively. The main AKI causes were leptospirosis (74.4%) and nephrotoxins (15.4%). Age (4.0 vs 5.4 years; P = 0.04), admission urine output (0.5 mL/kg/h vs 0 mL/kg/h; P = 0.02) and hospitalization length (10 vs 4 days; P < 0.001) differed between survivors and non-survivors. Hospitalization length [odds ratio (OR) = 0.4], number of treatments (OR = 5.1), serum potassium level on day 2 (OR = 1.9), DeltaCreat/h between the first and second treatments (OR = 1.2), and UOP during hospitalization (OR = 0.2) were correlated with outcome. The main causes of death were euthanasia (44%) and haemorrhagic diatheses (33%). The overall survival rate was 54%, with 55% of survivors discharged with a median creatinine < 240 µmol/L.

conclusionsThis is the first description in the veterinary literature of a 4-h protocol of intermittent low efficiency haemodiafiltration to provide RRT in a veterinary critical care unit. While this protocol appears promising, the clinical application of this protocol requires further investigation. Among parameters associated with survival, UOP and DeltaCreat/h between the first and second RRT treatments may be prognostic indicators. The applicability of these parameters to other populations is unknown, and further international, multicentre prospective studies are warranted to confirm these preliminary observations.

Indexed as

Acute Kidney InjuryAnimalsDog DiseasesDogsFemaleHemodiafiltrationMaleRetrospective StudiesTreatment OutcomeAcute renal failureOutcomePrognostic factorsRenal replacement therapyUrinary output

Identifiers

PMID30971317
PMCPMC6457005
OpenAlexW2943783992

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.